LB Pharmaceuticals Inc (LBRX) stock
LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$40.30−2.69 (-6.26%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Earnings
LB Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$1.79
-$0.61 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of LB Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | – | – | -$1.79 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | – | – | -$1.71 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026after the close | – | – | -$0.67 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 26, 2026after the close | – | – | -$0.45 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | – | – | -$0.61 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
LB Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When LB Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases LB Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- News
- Results
- Results
- Update
- Update
- News
- Results
See a number that looks wrong?